|
|
|
| Therapeutic Effect of Methimazole combined with Bisoprolol on Hyperthyroidism and its Influence on Serum OCN and beta-CTx |
| LI Jingdong, LUO Foule, LIANG Chongshang |
| 215 Hospital of Nuclear Industry of Shaanxi, Shaanxi Xianyang 712000, China |
|
|
|
|
Abstract Objective: To analyze the therapeutic effect of methylthimidazole combined with bisoprolol on hyperthyroidism and its effect on serum osteocalcin (OCN) and specific sequence of collagen type I carboxyterminal peptide beta (beta-CTx). Methods: 85 patients with hyperthyroidism admitted to our hospital from February 2015 to February 2017 were selected as the subjects of this study. They were divided into observation group (n=50) and control group (n=50) by simple random number table method. The control group was treated with methimazole combined with propranolol, while the observation group was treated with methimazole combined with bisoprolol for 14 consecutive days. The clinical efficacy, thyroid hormone function, serum OCN, beta-CTx changes and adverse reactions were compared between the two groups. Results: After treatment, the total effective rate of the observation group was significantly higher than that of the control group (P＜0.05); After treatment, the thyroid stimulating hormone (TSH) of two groups were significantly higher than before treatment. TSH in the observation group was significantly higher than that in the control group, FT4 and FT3 were significantly lower than those in the control group (P<0.05). After treatment, the levels of serum OCN and beta-CTx in the two groups were significantly lower than those before treatment (P<0.05). The levels of serum OCN and beta-CTx in the observation group were significantly lower than those in the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion: After treatment, the levels of serum OCN and beta-CTx in the two groups were significantly lower than those before treatment (P<0.05). The levels of serum OCN and beta-CTx in the observation group were significantly lower than those in the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).
|
|
|
|
|
|
[1] 彭力科.甲状腺功能亢进症流行病学特征研究进展[J].中国校医,2015,29(11):867~870.
[2] 周作荣,董娟,倪劲松.β受体阻滞剂和甲巯咪唑在老年毒性弥漫性甲状腺肿引起新发甲亢中的作用[J].中国预防医学杂志,2016,17(6):427~431
[3] 郭雨龙,刘爽.β受体阻滞剂对心血管病患者糖代谢的影响[J].心肺血管病杂志,2015,34(5):405~410.
[4] 李萌,李玉坤.骨转换标志物及其临床应用[J].临床荟萃,2014,29(1):104~108.
[5] 张燕燕,吴军.甲状腺功能异常患者血清FGF21水平与甲状腺激素骨代谢指标的关系[J].河北医学,2018(8):1266~1270.
[6] 葛均波,徐永健.内科学[M].北京:人民卫生出版社,2013.940~944.
[7] 韦耀丽.比索洛尔联合甲巯咪唑治疗老年亚临床甲状腺机能亢进症合并房颤疗效观察[J].吉林医学,2014,35(12):2567~2568.
[8] 张靓,杨田.比索洛尔治疗室性早搏的疗效及其对心脏自主神经功能的影响[J].海南医学,2015,26(23):3465~3467.
[9] 林源,于军,高海燕,等.比索洛尔联合甲巯咪唑对甲状腺功能亢进症患者糖脂代谢及血清CysC、β2-MG的影响[J].中国临床研究,2017,30(9):1195~1197,1200.
[10] 张萌萌.中国老年学学会骨质疏松委员会骨代谢生化指标临床应用专家共识[J].中国骨质疏松杂志,2014,20(11):1263~1272.
[11] 杜风丽,王娈,袁鹰.甲状腺功能亢进症患者治疗前后血清骨钙素和β-胶原特殊序列的变化[J].中华临床医师杂志(电子版),2013,7(6):2377~2380.
[12] 和渝斌,郭晓东,何冰娟,等.β受体阻滞剂比索洛尔对老年原发性高血压患者骨代谢的影响[J].中华老年心脑血管病杂志,2009,11(9):716~718. |
| [1] |
. [J]. 河北医学, 2017, 23(6): 1002-1004. |
|
|
|
|
2019, Vol. 25 
